Journal Article

Pharmacokinetics and Safety of Extemporaneously Compounded Valacyclovir Oral Suspension in Pediatric Patients from 1 Month through 11 Years of Age

David W. Kimberlin, Richard F. Jacobs, Stephen Weller, Jan-Stefan van der Walt, Catherine K. Heitman, Choy Y. Man and John S. Bradley

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 50, issue 2, pages 221-228
Published in print January 2010 | ISSN: 1058-4838
Published online January 2010 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/649212
Pharmacokinetics and Safety of Extemporaneously Compounded Valacyclovir Oral Suspension in Pediatric Patients from 1 Month through 11 Years of Age

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background

Valacyclovir provides enhanced acyclovir bioavailability in adults, but limited data are available in children.

Methods

Children 1 month through 5 years of age with or at risk for herpesvirus infection received a single 25 mg/kg dose of extemporaneously compounded valacyclovir oral suspension (n = 57), whereaschildren1through 11 years of age received 10 mg/kg valacyclovir oral suspension twice daily for 3–5 days (herpes simplex virus infection) (n = 28) or 20 mg/kg 3 times daily for 5 days (varicella-zoster virus infection) (n = 27). Blood samples for pharmacokinetic analysis were collected during the 6 h after the first dose. Safety was monitored throughout the studies.

Results

Dose proportionality in the maximum observed concentration (Cmax) of acyclovir and the area under the concentration-time curve from time zero extrapolated to infinity (AUC0−∞) existed across the 10 to 20 mg/kg valacyclovir dose range. For children 2 through 5 years of age, an increase in dose from 20 to 25 mg/kg resulted in near doubling of the Cmax and AUC0−∞. Among infants 1 through 2 months of age receiving 25 mg/kg, the mean AUC0−∞ and Cmax were higher (∼60% and 30%, respectively) than those among older infants and children receiving the same dose. Valacyclovir oral suspension was well tolerated. No clinically significant trends were noted in clinical chemical, hematologic, or urinalysis values from screening to follow-up.

Conclusions

Among children 3 months through 11 years of age, the 20 mg/kg dose of this formulation of valacyclovir oral suspension produces favorable acyclovir blood concentrations and is well tolerated. A dosing recommendation cannot be made for infants <3 months of age because of decreased clearance in this age group.

Trial registration

ClinicalTrials.gov identifier: NCT00297206.

Journal Article.  5111 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.